This report was first published by Endpoints News. To see the original version, click here
Boehringer Ingelheim will pair up with Simcere Pharmaceutical in one of the hottest targets in immunology.
For €42 million ($50 million) upfront, the German pharma will tap into Simcere’s preclinical TL1AxIL-23p19 bispecific antibody for inflammatory bowel disease, Simcere said in a Hong Kong Stock Exchange filing on Tuesday. The asset is codenamed SIM0709.
您已阅读15%（448字），剩余85%（2599字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。